Table of Contents GBI Research Report Guidance 2 Executive Summary 3 Table of Contents 4 List of Tables 6 List of Figures 16 Introduction 20 GBI Research Report Coverage 20 Tuberculosis Overview 20 Pneumonia 20 Methicillin-Resistant Staphylococcus aureus (MRSA) 21 Therapeutics Development 22 Tuberculosis 22 Pneumonia 24 Methicillin-Resistant Staphylococcus aureus (MRSA) 33 Therapeutics under Development by Companies 38 Tuberculosis 38 Pneumonia 41 Methicillin-Resistant Staphylococcus aureus (MRSA) 50 Therapeutics under Investigation by Universities/Institutes 55 Tuberculosis 55 Pneumonia 57 Methicillin-Resistant Staphylococcus aureus (MRSA) 60 Pipeline Products Glance 62 Tuberculosis 62 Pneumonia 65 Methicillin-Resistant Staphylococcus aureus (MRSA) 79 Products under Development by Companies 83 Tuberculosis 83 Pneumonia 86 Methicillin-Resistant Staphylococcus aureus (MRSA) 94 Products under Investigation by Universities/Institutes 101 Tuberculosis 101 Pneumonia 104 Methicillin-Resistant Staphylococcus aureus (MRSA) 106 Companies Involved in Therapeutics Development 109 Tuberculosis 109 Pneumonia 142 Methicillin-Resistant Staphylococcus aureus (MRSA) 203 Therapeutics Assessment 252 Tuberculosis 252 Pneumonia 263 Methicillin-Resistant Staphylococcus aureus (MRSA) 311 Dormant Projects 339 Tuberculosis 339 Pneumonia 343 Methicillin-Resistant Staphylococcus aureus (MRSA) 351 Discontinued Products 357 Tuberculosis 357 Pneumonia 357 Methicillin-Resistant Staphylococcus aureus (MRSA) 359 Product Development Milestones 360 Tuberculosis 360 Pneumonia 373 Methicillin-Resistant Staphylococcus aureus (MRSA) 405 Appendix 417 Methodology 417 Coverage 417 Secondary Research 417 Primary Research 417 Expert Panel Validation 417 Contact Us 417 Disclaimer 418

List of Tables Number of Products under Development for Tuberculosis 22 Number of Products under Development for Tuberculosis - Comparative Analysis 23 Number of Products under Development for Community Acquired Pneumonia 24 Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 25 Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25 Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 26 Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27 Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 28 Number of Products under Development for Pseudomonas aeruginosa Infections 29 Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis 30 Number of Products under Development for Klebsiella pneumoniae Infections 31 Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis 32 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis 34 Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35 Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36 Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 37 Number of Products under Development by Companies, Tuberculosis 38 Number of Products under Development by Companies, Community Acquired Pneumonia 41 Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 43 Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 45 Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46 Number of Products under Development by Companies, Klebsiella pneumoniae Infections 49 Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50 Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53 Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54 Number of Products under Investigation by Universities/Institutes, Tuberculosis 55 Number of Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 57 Number of Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 57 Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 58 Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59 Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60 Number of Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 61 Comparative Analysis by Late Stage Development, Tuberculosis 62 Comparative Analysis by Clinical Stage Development, Tuberculosis 63 Comparative Analysis by Early Stage Development, Tuberculosis 64 Comparative Analysis by Unknown Stage Development, Tuberculosis 65 Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65 Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66 Comparative Analysis by Early Stage Development, Community Acquired Pneumonia 67 Comparative Analysis by Late Stage Development, Hospital Acquired Pneumonia (HAP) 67 Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68 Comparative Analysis by Early Stage Development, Hospital Acquired Pneumonia (HAP) 69 Comparative Analysis by Unknown Stage Development, Hospital Acquired Pneumonia (HAP) 69 Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70 Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71 Comparative Analysis by Early Stage Development, Ventilator Associated Pneumonia (VAP) 72 Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73 Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74 Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75 Comparative Analysis by Early Stage Development, Pseudomonas aeruginosa Infections 76 Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77 Comparative Analysis by Late Stage Development, Klebsiella pneumoniae Infections 77 Comparative Analysis by Clinical Stage Development, Klebsiella pneumoniae Infections 78 Comparative Analysis by Early Stage Development, Klebsiella pneumoniae Infections 78 Comparative Analysis by Late Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79 Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79 Comparative Analysis by Early Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80 Comparative Analysis by Unknown Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 81 Comparative Analysis by Clinical Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81 Comparative Analysis by Early Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81 Comparative Analysis by Clinical Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 81 Comparative Analysis by Early Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82 Products under Development by Companies, Tuberculosis 83 Products under Development by Companies, Community Acquired Pneumonia 86 Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 88 Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 89 Products under Development by Companies, Pseudomonas aeruginosa Infections 89 Products under Development by Companies, Klebsiella pneumoniae Infections 93 Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 94 Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 100 Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 100 Products under Investigation by Universities/Institutes, Tuberculosis 101 Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 104 Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 104 Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 104 Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 106 Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 106 Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 108 Tuberculosis - Pipeline by Abera Bioscience AB, 109 Tuberculosis - Pipeline by Akthelia Pharmaceuticals Limited, 109 Tuberculosis - Pipeline by Alvogen Korea Co., Ltd., 110 Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., 111 Tuberculosis - Pipeline by Archivel Farma S.L., 111 Tuberculosis - Pipeline by AstraZeneca Plc, 112 Tuberculosis - Pipeline by Beech Tree Labs, Inc., 113 Tuberculosis - Pipeline by BioDiem Ltd, 113 Tuberculosis - Pipeline by BioLingus AG, 114 Tuberculosis - Pipeline by Biomar Microbial Technologies, 114 Tuberculosis - Pipeline by Bioversys AG, 115 Tuberculosis - Pipeline by Celgene Corporation, 115 Tuberculosis - Pipeline by Cellceutix Corporation, 116 Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., 116 Tuberculosis - Pipeline by Crestone, Inc., 117 Tuberculosis - Pipeline by Dafra Pharma International Ltd., 117 Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, 118 Tuberculosis - Pipeline by Demuris Limited, 118 Tuberculosis - Pipeline by Eisai Co., Ltd., 119 Tuberculosis - Pipeline by Eli Lilly and Company, 120 Tuberculosis - Pipeline by Ensol Biosciences Inc., 120 Tuberculosis - Pipeline by EpiVax, Inc., 121 Tuberculosis - Pipeline by FIT Biotech Oy, 121 Tuberculosis - Pipeline by GangaGen Inc., 122 Tuberculosis - Pipeline by GlaxoSmithKline Plc, 122 Tuberculosis - Pipeline by Globeimmune, Inc., 123 Tuberculosis - Pipeline by Hager Biosciences, LLC, 123 Tuberculosis - Pipeline by Hsiri Therapeutics LLC, 124 Tuberculosis - Pipeline by Imaxio SA, 124 Tuberculosis - Pipeline by Immunitor, Inc., 125 Tuberculosis - Pipeline by ImmunoBiology Limited, 125 Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., 126 Tuberculosis - Pipeline by Johnson & Johnson, 126 Tuberculosis - Pipeline by Lakewood-Amedex Inc, 127 Tuberculosis - Pipeline by Lipotek Pty Ltd., 127 Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. , 128 Tuberculosis - Pipeline by Microbion Corporation, 128 Tuberculosis - Pipeline by Microbiotix, Inc., 129 Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, 129 Tuberculosis - Pipeline by Novartis AG, 130 Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC, 130 Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., 131 Tuberculosis - Pipeline by QureTech Bio AB, 131 Tuberculosis - Pipeline by Recce Pty Ltd, 132 Tuberculosis - Pipeline by Rodos BioTarget GmbH, 132 List of Figures Number of Products under Development for Tuberculosis 22 Number of Products under Development for Tuberculosis - Comparative Analysis 23 Number of Products under Development for Community Acquired Pneumonia 24 Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25 Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 26 Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27 Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 28 Number of Products under Development for Pseudomonas aeruginosa Infections 29 Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis 30 Number of Products under Development for Klebsiella pneumoniae Infections 31 Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis 32 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis 34 Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35 Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36 Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 37 Number of Products under Development by Companies, Tuberculosis 38 Number of Products under Development by Companies, Community Acquired Pneumonia 41 Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 42 Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 44 Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46 Number of Products under Development by Companies, Klebsiella pneumoniae Infections 48 Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50 Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53 Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54 Number of Products under Investigation by Universities/Institutes, Tuberculosis 55 Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 57 Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59 Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60 Comparative Analysis by Late Stage Development, Tuberculosis 62 Comparative Analysis by Clinical Stage Development, Tuberculosis 63 Comparative Analysis by Early Stage Products, Tuberculosis 64 Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65 Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66 Comparative Analysis by Early Stage Products, Community Acquired Pneumonia 67 Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68 Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP) 69 Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70 Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71 Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP) 72 Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73 Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74 Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75 Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections 76 Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77 Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections 78 Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79 Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80 Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82 Assessment by Monotherapy Products, Tuberculosis 252 Assessment by Combination Products, Tuberculosis 253 Number of Products by Top 10 Targets, Tuberculosis 254 Number of Products by Stage and Top 10 Targets, Tuberculosis 254 Number of Products by Top 10 Mechanism of Actions, Tuberculosis 257 Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis 257 Number of Products by Top 10 Routes of Administration, Tuberculosis 260 Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis 260 Number of Products by Top 10 Molecule Types, Tuberculosis 262 Number of Products by Stage and Top 10 Molecule Types, Tuberculosis 262 Assessment by Monotherapy Products, Community Acquired Pneumonia 263 Number of Products by Targets, Community Acquired Pneumonia 264 Number of Products by Stage and Targets, Community Acquired Pneumonia 265 Number of Products by Mechanism of Actions, Community Acquired Pneumonia 266 Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia 266 Number of Products by Routes of Administration, Community Acquired Pneumonia 267 Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia 268 Number of Products by Molecule Types, Community Acquired Pneumonia 269 Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia 269 Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP) 270 Assessment by Combination Products, Hospital Acquired Pneumonia (HAP) 271 Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272 Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272 Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274 Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274 Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP) 276 Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP) 276 Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP) 277 Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP) 278 Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP) 279 Assessment by Combination Products, Ventilator Associated Pneumonia (VAP) 280 Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP) 281 Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP) 282 Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 284 Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 285 Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 287 Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 288 Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 289 Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 290 Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections 291 Assessment by Combination Products, Pseudomonas aeruginosa Infections 292 Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections 293 Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections 293 Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 295 Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 296 Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections 299 Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections 299 Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301 Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301 Assessment by Monotherapy Products, Klebsiella pneumoniae Infections 303 Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections 304 Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections 304 Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306 Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306 Number of Products by Routes of Administration, Klebsiella pneumoniae Infections 308 Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections 308 Number of Products by Molecule Types, Klebsiella pneumoniae Infections 309 Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections 310 Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 311 Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 312 Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313 Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313 Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316 Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316 Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319 Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319 Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321 Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321 Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 323 Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324 Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324 Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 325 Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 326 Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327 Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327 Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329 Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329 Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 330 Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331 Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331 Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333 Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333 Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335 Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335 Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 337 Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 33